39 results about "Heart transplants" patented technology

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart.

A percutaneous implanted device for temporarily sustaining a patient awaiting a heart transplant. The device includes a radially expandable stent mounted upon the balloon section of a balloon catheter. A venous biological valve is mounted at each end of the stent and an inflatable annular-shaped diaphragm is secured to the stent between the valves, which permit the flow of blood in one direction and prevent the flow of blood in the opposite direction. The diaphragm is attached to a pump which inflates the diaphragm after the stent is implanted in a blood vessel in relation to the heart's rhythm to assist the heart in moving blood through the patient's circulatory system.

The invention discloses a new use of an aryl urea derivative in the preparation of a medicine for treating transplant rejection. The aryl urea derivative is 1-(3-(trifluoromethyl)-4-chloro-phenyl)-3-(3-(6-(1-methyl-4-pyrazolyl)-4-oxypyrimidine)-6-fluorine-phenyl) urea. The compound disclosed by the invention can obviously relieve the rejection reaction of the body to transplanted organs and improve the functions of transplanted organs and can be used for preparing the medicine for preventing and curing organ transplant rejection reaction, in particular the medicine for preventing immune rejection reaction after kidney, liver or heart transplant.

The invention relates to a mycophenolic acid derivative as shown in a formula V and a pharmaceutically acceptable salt thereof, wherein L is -O-R2, -QCOOR2 or -QCONR2R3, Q is alkylene of C1 to C10 or alkenylene of C1 to C6, and -O-R1, or -O-*M+. The invention further relates to a pharmaceutical composition containing the mycophenolic acid derivative, the pharmaceutically acceptable salt and pharmaceutical adjuvants, a preparation method of the mycophenolic acid derivative and the pharmaceutically acceptable salt, and an application of the mycophenolic acid derivative and the pharmaceutically acceptable salt in immunosuppressant drugs, especially in preparing drugs for treating organ transplants such as skin transplant, liver transplant and heart transplant, and autoimmune diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, lupus nephritis, IgA nephritis, glomerulus nephritis, etc.

The current invention relates to an implantable device, system, method, and computer readable medium comprising computer executable components for detection of rejection of a cardiac allograft. Acute rejection and chronic rejection are the leading cause of death in heart transplant recipients post transplant. The current invention seeks to address this problem by providing methods, devices, systems and computer readable media comprising computer executable components to monitor the efficacy of immunosuppressant therapy and evaluate the degree of rejection in a cardiac allograft. To provide this functionality, an implantable device comprises sensors which measure physiologic parameters at specified intervals after the transplant procedure. These measured parameters are subsequently compared with baseline parameter data to detect rejection of the cardiac allograft.

The invention relates to a hemolysis-free continuous isolated heart transfer device which comprises a box body and a box cover, a circulating liquid cavity and a heart placing cover are arranged in the box body, the heart placing cover is of a solid net-shaped structure similar to the shape of the heart, two blood vessel penetrating-out connectors are arranged on the heart placing cover, a displacement pump circulating device is arranged in the circulating liquid cavity, a liquid inlet pipe and a liquid outlet pipe are connected to the displacement pump circulating device, the liquid inlet pipe and the liquid outlet pipe are aligned to the two blood vessel penetrating-out connectors respectively, and elastic ribbons are arranged on the blood vessel penetrating-out connectors. In the heart transfer process, the heart can be kept in a circulating state, meanwhile, blood cell damage is effectively reduced, damage to the heart caused by in-vitro transfer is reduced, and the heart transplantation success rate is increased.

The invention is a method for treating a heart failure patient with the steps of measuring the concentration of IGFBP2 in a blood, plasma or urine sample obtained from the heart failure patient and comparing the patient's IGFBP2 level to a threshold value derived from IGFBP2 measured in samples taken from a group of patients with heart failure selected from the group consisting of stage I, stage stage III and stage IV heart failure, according to New York Heart Association (NYHA) classification system. A patient with an IGFBP2 level that exceeds the threshold value is admitted or readmitted to a hospital and treated with at least one treatment selected from the group consisting of administration of a beta-blocker, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, an aldosterone antagonist, an implantable cardiac defibrillator, a cardiac resynchronization therapy, an implantable left ventricular assist device and a heart transplant.

The invention discloses a fixator for a cardiac surgery transplantation operation and a using method thereof, and relates to the technical field of heart transplantation. The fixator comprises a fixator body, side sliding grooves are formed in the two corresponding sides of the fixator body, first sliding blocks are slidably connected into the two side sliding grooves, outer mounting blocks are fixedly mounted on one sides of the two first sliding blocks, first rotating grooves are formed in one sides of the outer mounting blocks, and first rotating connecting columns are rotationally connected into the first rotating grooves. The fixator for the cardiac surgery transplantation operation has the beneficial effects that the two sets of main clamping frames and an auxiliary fixing frame are used, the auxiliary fixing frame can be used for fixing a heart from the lower portion of the heart, the main clamping frames are used for fixing the heart from the two sides of the heart, therefore the heart can be more conveniently fixed, and through a multi-section type rotating mechanism of the auxiliary fixing frame, the fixator can better conform to the surface contour of the heart and is more convenient to use.

The invention relates to the technical field of Fontan postoperative adjuvant treatment apparatus, in particular to a novel auxiliary device for the treatment of Fontan circulatory failure. The novelauxiliary device for the treatment of the Fontan circulatory failure includes a balloon, the balloon is placed at the intersection of pulmonary arteries, superior vena cava and inferior vena cava after Fontan operation; the two ends of the balloon are separately located in the superior vena cava and inferior vena cava; and as the balloon is inflated and deflated, blood in the superior vena cava and the inferior vena cava is squeezed into the pulmonary arteries. Through the way, the balloon is placed at the intersection of the pulmonary arteries, the superior vena cava and the inferior vena cava, through the inflation and deflation of the balloon, the balloon expands and contracts, and then the blood in the superior vena cava and the inferior vena cava is squeezed into the pulmonary arteries. Valves coupled with the balloon are opened and closed simultaneously to prevent the blood from flowing back to the superior vena cava and the inferior vena cava, so that the blood pulsates into thepulmonary arteries to play a role of a part of a right ventricular, so that patients with the Fontan circulatory failure are treated, and strong conditions are provided for later heart transplant operation.

The invention discloses a thoracic cavity opening device and method for a heart transplantation operation, and relates to the technical field of heart transplantation. The thoracic cavity opening device comprises a fixed arm, an adjusting box is fixedly connected to the top of the fixed arm, a moving groove is formed in the bottom of the fixed arm, a fixed plate is fixedly connected to the middle of the top of an inner cavity of the moving groove, and two sides of the fixed plate are respectively and rotatably connected with a screw rod; according to the thoracic cavity opening device for the heart transplantation operation, by arranging a rotating column, the rotating rod and the screw rods, the rotating column drives the rotating rod to rotate when rotating, so that the two screw rods rotate, two moving arms can move at the same time, and the thoracic cavity is opened; and a screw and a threaded groove are arranged, when the opening position of one moving arm needs to be finely adjusted in operation, the screw above the other moving arm is screwed, the bottom end of the screw extends to the inside of the threaded groove, and the bottom end ofthe screw is in threaded connection with the thread groove, so that the other moving arm cannot be rotated, and adjustment is facilitated.

The invention discloses application of a PCSK9 inhibitor in anti-rejection after cardiac transplantation. The PCSK9 inhibitor is alirocumab, a usage mode of the PCSK9 inhibitor is of subcutaneous injection, and the dosage of use is 10mg/kg/week. According to the application of the PCSK9 inhibitor in the anti-rejection after the cardiac transplantation, provided by the invention, compared with that a rejection after cardiac transplantation is treated by purely using an immunosuppressant at present, after combined application of the PCSK9 inhibitor, the alleviation of an immunologic rejection after cardiac transplantation and the prolonging of survival time of a heart transplant are better facilitated. Furthermore, the survival cycle of the transplant can also be effectively prolonged by independently using the PCSK9 inhibitor.

The present invention relates to a pruning and measuring device for the left atrium of a transplanted heart, and a use method of the pruning and measuring device. The pruning and measuring device comprises an elliptical measuring plate, and an operating rod vertically passing through the measuring plate, wherein the edge of the measuring plate is connected with an adjustment airbag, a sealed inflation cavity is formed between the measuring plate and the adjustment airbag, one end of the operating rod penetrates through the adjustment airbag and is connected with a positioning airbag, the otherend of the operating rod is provided with a hand-pinch type airbag, a ventilation groove is arranged in the operating rod, a section, located in the adjustment airbag, of the operating rod is provided with ventilation holes, the hand-pinch airbag, the positioning airbag and the adjustment airbag communicate with each other through the ventilation groove and the ventilation holes, and the hand-pinch airbag is provided with a one-way air inlet valve. The pruning and measuring device is used for pruning the left atrium of a transplanted heart before a heart transplantation operation, and can measure and mark a size of an incision to be pruned and a tissue removal amount according to needs, so that the accurate pruning is ensured, and the operation difficulty is reduced.

The invention discloses a surgical retractor for heart transplantation and a using method thereof, and relates to the technical field of medical instruments, in particular to a surgical retractor for heart transplantation. Thesurgical retractor comprises a retractor rod, a retractor box is clamped on the surface of the retractor rod, an adjusting box is fixedly connected to one end of the retractor rod, and a storage chamber is formed in the adjusting box. And a second lead screw is movably connected to an inner cavity of the storage chamber in a sleeving mode, and a second servo motor is fixedly mounted at the top of the adjusting box. According to the operation retractor for heart transplantation, through cooperative use of an adjusting box, a second lead screw, a first retractor body and a tooth-shaped connecting block, in the heart transplantation operation process, the thickness of the skin and fat of the thoracic cavity of a patient is observed firstly, and then the second servo motor is started to drive the second lead screw to rotate; and a first retractor is driven to move up and down through meshing transmission of the second lead screw and the tooth-shaped connecting block, the function of adjusting the length of the first retractor is achieved, and the stability of the surgical retractor for heart transplantation is improved.

The invention provides an application of JQ1 in preparing organ transplantation immunological rejection inhibiting medicines, in particular an application in preparing medicines for preventing and treating cardiac transplantation immunological rejection. Based upon experiments, it is proved that the survival time of transplanted hearts of an allogeneic mice (C57BL/6 to BALB/c) in a control group is 7-10 days, while the survival time of transplanted hearts of mice applied with the JQ1 can reach 25 days to the greatest extent, indicating that the JQ1 provided by the invention is beneficial for reducing an alloimmunity reaction and prolonging the survival of transplants. The JQ1, as a novel small-molecule inhibitor, can solve the problem that transplanted organs are low in survival rate for along time due to rejection, and the JQ1 can offer a basis for preparing organ transplantation immunological rejection inhibiting preparations; therefore, an effective approach is provided for treating such chronic end-stage diseases such as liver diseases, renal diseases, cardiac diseases and the like.